Research LettersMetformin in non-alcoholic steatohepatitis
References (5)
- et al.
Association of nonalcoholic fatty liver disease to insulin resistance
Am J Med
(1999) - et al.
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
Am J Gastroenterol
(2001)
There are more references available in the full text version of this article.
Cited by (649)
Metformin improves nonalcoholic fatty liver disease in db/db mice by inhibiting ferroptosis
2024, European Journal of PharmacologyMetformin potentiates immunosuppressant activity and adipogenic differentiation of human umbilical cord-mesenchymal stem cells
2023, International ImmunopharmacologyOptimization of preparation method of hepatoprotective active components from Coreopsis tinctoria Nutt. and its action mechanism in vivo
2023, Biomedicine and PharmacotherapyCombination of metformin and genistein alleviates non-alcoholic fatty liver disease in high-fat diet-fed mice
2021, Journal of Nutritional BiochemistryCitation Excerpt :The activation of AMPK is associated with inhibiting lipogenesis and gluconeogenesis and enhancing insulin sensitivity in liver [19]. There is some evidence showing that MET might be beneficial in improvement of hepatic steatosis and inflammation [7,20,21]. Despite the beneficial effects of MET, this drug has been reported to have several side effects such as gastrointestinal disorders including bloating, nausea, heartburn, diarrhea and malabsorption of vitamin B12.
Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease
2024, Lipids in Health and DiseaseUnveiling global research trends and hotspots on mitochondria in NAFLD from 2000 to 2023: A bibliometric analysis
2024, Immunity, Inflammation and Disease
Copyright © 2001 Elsevier Ltd. All rights reserved.